文献速递流行病学与生物统计基础与转化研究

孤儿药研发中早期与后期结局的联合评估

Combined assessment of early and late-phase outcomes in orphan drug development.
PubMed 文献 · Stat Med · 2021-04-04

在孤儿药研发中,II期试验常以生物标志物或短期结局为主要终点,III期试验则以需更长随访的临床结局验证疗效。本文针对罕见病仅有单个II期和III期试验的情形,提出双重回归建模及贝叶斯双重回归方法,对II期早期结局与III期后期结局进行正式回顾性联合评估,并以法布雷病孤儿药案例展示各方法。

要点

  • II期早期结局常被视作III期后期结局的佐证,但缺乏正式联合评估。
  • 双重回归建模可数值模拟非正式回顾性评估,并给出偏倚与均方误差的解析解。
  • 贝叶斯双重回归通过折扣II期早期结局来最小化研究间差异所致偏倚。

核心结论

  • 对II期早期结局与III期后期结局进行正式联合评估可纠正非正式回顾性评估的偏倚。
  • 贝叶斯双重回归通过折扣与III期生物标志物结果不一致的II期早期结局来最小化偏倚。

研究设计与样本

  • 方法学研究,应用双重回归建模于II期和III期结果以模拟非正式回顾性评估。
  • 提出贝叶斯双重回归方法,并以法布雷病孤儿药案例进行展示。

主要发现

  • 给出了总体效应偏倚与均方误差的解析解,并据此构建校正双重回归。
  • 贝叶斯双重回归通过折扣II期早期结局来考虑研究间差异。

临床怎么用

  • 在罕见病仅有单个II期和III期试验时,可用双重回归对早期与后期结局做正式联合评估。
  • 当II期早期结局与III期生物标志物结果不一致时,贝叶斯双重回归可折扣II期信息以减小偏倚。

局限性

  • 方法以法布雷病孤儿药案例展示,未报告其他疾病或更广泛场景的验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In drug development programs, proof-of-concept Phase II clinical trials typically have a biomarker as a primary outcome, or an outcome that can be observed with relatively short follow-up. Subsequently, the Phase III clinical trials aim to demonstrate the treatment effect based on a clinical outcome that often needs a longer follow-up to be assessed. Early-phase outcomes or biomarkers are typically associated with late-phase outcomes and they are often included in Phase III trials. The decision to proceed to Phase III development is based on analysis of the early-Phase II outcome data. In rare diseases, it is likely that only one Phase II trial and one Phase III trial are available. In such cases and before drug marketing authorization requests, positive results of the early-phase outcome of Phase II trials are then likely seen as supporting (or even replicating) positive Phase III results on the late-phase outcome, without a formal retrospective combined assessment and without accounting for between-study differences. We used double-regression modeling applied to the Phase II and Phase III results to numerically mimic this informal retrospective assessment. We provide an analytical solution for the bias and mean square error of the overall effect that leads to a corrected double-regression. We further propose a flexible Bayesian double-regression approach that minimizes the bias by accounting for between-study differences via discounting the Phase II early-phase outcome when they are not in line with the Phase III biomarker outcome results. We illustrate all methods with an orphan drug example for Fabry disease.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Pateras K, Nikolakopoulos S, Roes KCB, et al. Combined assessment of early and late-phase outcomes in orphan drug development. Stat Med. 2021. PMID: 33813759. doi:10.1002/sim.8952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。